English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

UGDP. Spurious results and biologically inappropriate data analysis. Diabetologia 18: 179±185 6. Knowler WC, Sartor G, Melander A, Scherstein B (1997) Glucose tolerance and mortality, including a substudy of tolbutamid treatment. Diabetologia 40: 680±686 7. Turner RC, Millns H, Holmann RR (1997) Coronary heart disease and risk factors in NIDDM ± experience from the United Kingdom Prospective Diabetes Study. Diabetologia 40:S121±S122 8. Shimabukura M, Nagamine F, Murakami K, Oshiro K, Mimura G (1994) Chronic gliclazide treatment affects basal and post-ischemic cardiac function in diabetic rats. Gen Pharmacol 25: 697±704 9. McDonagh PF, Hokama JY, Copeland JG, Reynolds JM (1997) The blood contribution to early myocardial reperfusion injury is amplified in diabetes: Diabetes 46: 1859±1867 10. Leibowitz G, Cerasi E (1996) Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing ? Diabetologia 39: 503±514

Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease